Navigation Links
Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
Date:5/24/2013

WELWYN GARDEN CITY, England and BOSTON, May 24, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akira Usui as a Consultant to augment the Company's business development capabilities in Japan and other Asian territories.

Mr Usui has more than 15 years of experience in business development, licensing and alliance management in the pharmaceutical industry including senior roles at Perlegen Sciences, Inc., Roche Pharma (Japan), Nippon Roche and Tanabe Seiyaku Co. Ltd. Mr Usui is President of Ray Life Sciences Inc., which he established in 2007 to provide business and corporate development consulting services to pharma and biotech companies, universities and venture capital firms with a specific focus on the Japanese market.

Barry Kenny , Heptares' Chief Business Officer, said: "Akira has an exceptional depth of experience in business development and an impressive track record in implementing agreements across multiple international territories. In addition to our existing partnership with Takeda, we are developing significant interest from pharmaceutical companies in Japan in what Heptares' technology can offer. We look forward to working with Akira, who will provide additional support in this region, to manage and advance these multiple new business opportunities for our unique GPCR-focused drug discovery and development capabilities."  

Mr Usui added: "Heptares has established itself as the leader in GPCR-focused drug discovery and has achieved significant milestones both with its partners and in building its own pipeline of drug candidates. Its platform and approach has the potential to unlock the GPCR space to drug discovery and enable the development of new and better targeted medicines for diseases with few effective treatments. I am delighted to work with the Company as it seeks to increase its business development activities in Japan and Asia."

 

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares and UK Medical Research Council Extend GPCR Collaboration
2. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
3. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
4. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
5. Generex Augments Antigen Express Scientific Advisory Board
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
9. Nominations Open for San Francisco Business Times Health Care Heroes Awards
10. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
11. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology:
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... prolapse with the latest techniques and the most minimally invasive approaches. , Women ... prolapse, particularly after menopause. Other risk factors include surgery to the pelvic floor, ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... program. MyDecision™ empowers employers and organizations with the tools and information to lower ... three elements to cut the cost of providing employee healthcare benefits by as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):